World Psoriasis Day News: Upcoming H&W Global Dermatology CME Conference to Address Need for Improved Management of Psoriatic Disease

October 29, 2025

An Easy Pill to Swallow: PsO Patients, Providers Would Prefer Pill Over Injectables, Topicals

October 27, 2025

Fall Clinical 2025 News: Oral Icotrokinra Shows High Clearance in Difficult-to-treat Scalp and Genital Psoriasis

October 24, 2025

Done Deal: LEO Pharma Closes Deal for BI’s Spesolimab (Spevigo)

October 2, 2025

U.S. FDA Approves Guselkumab for Pediatric Psoriasis and Active PsA

September 29, 2025

BMS Offers Deep Discounts on Deucravacitinib (Sotyktu)

September 28, 2025

Battle of the PsO Pills: Investigational Icotrokinra Bests Deucravacitinib (Sotyktu, BMS) in Phase 3 Trials

September 18, 2025

Tildrakizumab (Ilumetri, Almirall) Shows Sustained Improvements in Skin and Quality of Life in PsO Patients; Study Uses WHO 5 Well-Being Index as Primary Endpoint

September 18, 2025

WHO Adds Biologics for Psoriasis and Sunscreen for Albinism to Essential Medicines List

September 15, 2025

First Off: Johnson & Johnson Submits Application to EMA for Oral Icotrokinra in Psoriasis

September 11, 2025

Arcutis Submits sNDA for Roflumilast Cream 0.3% (Zoryve) for Psoriasis in Children Down to Age 2

September 3, 2025

NPF Hosts Its First-ever Total Body Wellness Day: Find Out What to Expect

August 26, 2025